

Marco Falcone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9006922/publications.pdf>

Version: 2024-02-01

203
papers

9,645
citations

44069

48
h-index

48315

88
g-index

207
all docs

207
docs citations

207
times ranked

11874
citing authors

#	ARTICLE	IF	CITATIONS
1	Bloodstream infections in patients with rectal colonization by <i>Klebsiella pneumoniae</i> producing different type of carbapenemases: a prospective, cohort study (CHIMERA study). <i>Clinical Microbiology and Infection</i> , 2022, 28, 298.e1-298.e7.	6.0	27
2	Corticosteroid use, myocardial injury and in-hospital cardiovascular events in patients with community-acquired pneumonia. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 155-165.	2.4	6
3	What COVID-19 taught us: New opportunities and pathways from telemedicine and novel antiseptics in wound healing. <i>International Wound Journal</i> , 2022, 19, 987-995.	2.9	10
4	Ocular toxoplasmosis, an overview focusing on clinical aspects. <i>Acta Tropica</i> , 2022, 225, 106180.	2.0	12
5	Therapeutic Drug Monitoring of Antibiotics in the Elderly: A Narrative Review. <i>Therapeutic Drug Monitoring</i> , 2022, 44, 75-85.	2.0	7
6	What have we learned from the first to the second wave of COVID-19 pandemic? An international survey from the ESCMID Study Group for Infection in the Elderly (ESGIE) group. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2022, 41, 281-288.	2.9	8
7	ECMO in COVID-19 Patients: A Systematic Review and Meta-analysis. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2022, 36, 2700-2706.	1.3	55
8	Management of COVID patients with convalescent plasma: Do we have the final word?. <i>European Journal of Internal Medicine</i> , 2022, 95, 13-16.	2.2	3
9	Comparison of Thrombotic Events and Mortality in Patients with Community-Acquired Pneumonia and COVID-19: A Multicenter Observational Study. <i>Thrombosis and Haemostasis</i> , 2022, 122, 257-266.	3.4	18
10	Spread of hypervirulent multidrug-resistant ST147 <i>Klebsiella pneumoniae</i> in patients with severe COVID-19: an observational study from Italy, 2020-21. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1140-1145.	3.0	20
11	Cefiderocol for the Treatment of Metallo- β -Lactamases Producing Gram-Negative Bacilli: Lights and Shadows From the Literature. <i>Clinical Infectious Diseases</i> , 2022, 75, 1085-1087.	5.8	8
12	Early Use of Remdesivir and Risk of Disease Progression in Hospitalized Patients With Mild to Moderate COVID-19. <i>Clinical Therapeutics</i> , 2022, 44, 364-373.	2.5	22
13	Patterns of Long COVID Symptoms: A Multi-Center Cross Sectional Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 898.	2.4	33
14	Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : a multicentre study. <i>JAC-Antimicrobial Resistance</i> , 2022, 4, dlac022.	2.1	17
15	The ADA (Age-D-Dimer-Albumin) Score to Predict Thrombosis in SARS-CoV-2. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1567-1572.	3.4	11
16	Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant <i>Acinetobacter baumannii</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0214221.	3.2	93
17	Multidrug-resistant infections in solid organ transplant recipients: a focus on risk factors, prevention and treatment strategies. <i>Minerva Anestesiologica</i> , 2022, , .	1.0	0
18	Caring for older adults during the COVID-19 pandemic. <i>Clinical Microbiology and Infection</i> , 2022, 28, 785-791.	6.0	21

#	ARTICLE	IF	CITATIONS
19	Role of dalbavancin as combination therapy: evidence from the literature and clinical scenarios. Expert Review of Anti-Infective Therapy, 2022, 20, 997-1004.	4.4	4
20	Multicenter, Prospective Validation of a Phenotypic Algorithm to Guide Carbapenemase Testing in Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> Using the ERACE-PA Global Surveillance Program. Open Forum Infectious Diseases, 2022, 9, ofab617.	0.9	3
21	Effectiveness and safety of colistin among older adults: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2022, 77, 2094-2104.	3.0	4
22	Superinfections caused by carbapenem-resistant Enterobacterales in hospitalized patients with COVID-19: a multicentre observational study from Italy (CREVID Study). JAC-Antimicrobial Resistance, 2022, 4, .	2.1	13
23	Diagnosis and management of infections caused by multidrug-resistant bacteria: guideline endorsed by the Italian Society of Infection and Tropical Diseases (SIMIT), the Italian Society of Anti-Infective Therapy (SITA), the Italian Group for Antimicrobial Stewardship (GISA), the Italian Association of Clinical Microbiologists (AMCLI) and the Italian Society of Microbiology (SIM). International Journal of Antimicrobial Agents, 2022, 60, 106611.	2.5	36
24	Daptomycin Population Pharmacokinetics in Patients Affected by Severe Gram-Positive Infections: An Update. Antibiotics, 2022, 11, 914.	3.7	5
25	Association Between Minimum Inhibitory Concentration, Beta-lactamase Genes and Mortality for Patients Treated With Piperacillin/Tazobactam or Meropenem From the MERINO Study. Clinical Infectious Diseases, 2021, 73, e3842-e3850.	5.8	82
26	Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo- β -lactamase-Producing Enterobacterales. Clinical Infectious Diseases, 2021, 72, 1871-1878.	5.8	191
27	Interpreting procalcitonin in patients undergoing hemodialysis: a reliable or a misleading marker?. Internal and Emergency Medicine, 2021, 16, 11-13.	2.0	1
28	Effect of Tocilizumab vs Standard Care on Clinical Worsening in Patients Hospitalized With COVID-19 Pneumonia. JAMA Internal Medicine, 2021, 181, 24.	5.1	593
29	JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality. Science Advances, 2021, 7, .	10.3	176
30	Broadly reactive human CD4 ⁺ T cells against Enterobacteriaceae are found in the naïve repertoire and are clonally expanded in the memory repertoire. European Journal of Immunology, 2021, 51, 648-661.	2.9	13
31	Predictors of intensive care unit admission in patients with Legionella pneumonia: role of the time to appropriate antibiotic therapy. Infection, 2021, 49, 321-325.	4.7	18
32	Cefiderocol as Rescue Therapy for <i>Acinetobacter baumannii</i> and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients. Clinical Infectious Diseases, 2021, 72, 2021-2024.	5.8	94
33	Ceftazidime-Avibactam Use for <i>Klebsiella pneumoniae</i> Carbapenemase-Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. Clinical Infectious Diseases, 2021, 73, 1664-1676.	5.8	130
34	Community-acquired Pneumonia Owing to Multidrug-Resistant Pathogens: A Step toward an Early Identification. Annals of the American Thoracic Society, 2021, 18, 211-213.	3.2	7
35	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients with COVID-19: A Multicenter Study. Journal of Clinical Medicine, 2021, 10, 555.	2.4	93
36	Thyroid cancer and COVID-19: experience at one single thyroid disease referral center. Endocrine, 2021, 72, 332-339.	2.3	10

#	ARTICLE	IF	CITATIONS
37	Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512 <i>Klebsiella pneumoniae</i> Producing KPC-31, a D179Y Variant of KPC-3. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab141.	0.9	36
38	The relationship between cardiac injury, inflammation and coagulation in predicting COVID-19 outcome. <i>Scientific Reports</i> , 2021, 11, 6515.	3.3	11
39	The role of dalbavancin for Gram positive infections in the COVID-19 era: state of the art and future perspectives. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1125-1134.	4.4	11
40	Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). <i>Clinical Microbiology and Infection</i> , 2021, 27, 389-395.	6.0	37
41	Low diaphragm muscle mass predicts adverse outcome in patients hospitalized for COVID-19 pneumonia: an exploratory pilot study. <i>Minerva Anestesiologica</i> , 2021, 87, 432-438.	1.0	24
42	Diabetes and acute bacterial skin and skin structure infections. <i>Diabetes Research and Clinical Practice</i> , 2021, 174, 108732.	2.8	20
43	Diagnostic stewardship based on patient profiles: differential approaches in acute versus chronic infectious syndromes. <i>Expert Review of Anti-Infective Therapy</i> , 2021, 19, 1373-1383.	4.4	5
44	Education: An overview from the author of Cefiderocol as rescue therapy for <i>Acinetobacter baumannii</i> and other carbapenem-resistant Gram-negative infections in intensive care unit patients. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, i25-i25.	2.1	2
45	Pharmacokinetics of Non- β -Lactam β -Lactamase Inhibitors. <i>Antibiotics</i> , 2021, 10, 769.	3.7	11
46	Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100016.	1.0	5
47	How to: prophylactic interventions for prevention of <i>Clostridioides difficile</i> infection. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1777-1783.	6.0	15
48	The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant <i>Pseudomonas aeruginosa</i> . <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 2533-2541.	2.9	48
49	Efficacy of Bamlanivimab/Etesevimab and Casirivimab/Imdevimab in Preventing Progression to Severe COVID-19 and Role of Variants of Concern. <i>Infectious Diseases and Therapy</i> , 2021, 10, 2479-2488.	4.0	69
50	Elevated MICs of Susceptible Anti-Pseudomonal Cephalosporins in Non-Carbapenemase-Producing, Carbapenem-Resistant <i>Pseudomonas aeruginosa</i> : Implications for Dose Optimization. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0120421.	3.2	6
51	Challenges in the management of chronic wound infections. <i>Journal of Global Antimicrobial Resistance</i> , 2021, 26, 140-147.	2.2	56
52	Fatal fungemia by biofilm-producing <i>Trichosporon asahii</i> in a liver transplant candidate. <i>Infezioni in Medicina</i> , 2021, 29, 464-468.	1.1	0
53	Prevention of the spread of multidrug-resistant organisms in nursing homes. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 679-687.	2.9	8
54	Predictors of hospital-acquired bacterial and fungal superinfections in COVID-19: a prospective observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1078-1084.	3.0	112

#	ARTICLE	IF	CITATIONS
55	Pragmatic options for dose optimization of ceftazidime/avibactam with aztreonam in complex patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1025-1031.	3.0	18
56	Estimated pulse wave velocity improves risk stratification for all-cause mortality in patients with COVID-19. <i>Scientific Reports</i> , 2021, 11, 20239.	3.3	22
57	Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia. <i>JAMA Network Open</i> , 2021, 4, e2136246.	5.9	50
58	Real-world corticosteroid use in severe pneumonia: a propensity-score-matched study. <i>Critical Care</i> , 2021, 25, 432.	5.8	11
59	Predictors of mortality in solid organ transplant recipients with bloodstream infections due to carbapenemase-producing Enterobacterales: The impact of cytomegalovirus disease and lymphopenia. <i>American Journal of Transplantation</i> , 2020, 20, 1629-1641.	4.7	17
60	Interplay between Nox2 Activity and Platelet Activation in Patients with Sepsis and Septic Shock: A Prospective Study. <i>Oxidative Medicine and Cellular Longevity</i> , 2020, 2020, 1-6.	4.0	4
61	Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa563.	0.9	48
62	Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. <i>Diabetes Care</i> , 2020, 43, 2345-2348.	8.6	133
63	A systematic review assessing the under-representation of elderly adults in COVID-19 trials. <i>BMC Geriatrics</i> , 2020, 20, 538.	2.7	38
64	Considerations for the optimal management of antibiotic therapy in elderly patients. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 22, 325-333.	2.2	27
65	Pulmonary Aspergillosis: An Evolving Challenge for Diagnosis and Treatment. <i>Infectious Diseases and Therapy</i> , 2020, 9, 511-524.	4.0	45
66	Ceftolozane/Tazobactam for Treatment of Severe ESBL-Producing Enterobacterales Infections: A Multicenter Nationwide Clinical Experience (CEFTABUSE II Study). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa139.	0.9	49
67	Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo- β -Lactamase-Producing Enterobacterales During a Regional Outbreak. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa011.	0.9	47
68	Time to appropriate antibiotic therapy is a predictor of outcome in patients with bloodstream infection caused by KPC-producing <i>Klebsiella pneumoniae</i> . <i>Critical Care</i> , 2020, 24, 29.	5.8	121
69	Extremely drug-resistant NDM-9-producing ST147 <i>Klebsiella pneumoniae</i> causing infections in Italy, May 2020. <i>Eurosurveillance</i> , 2020, 25, .	7.0	36
70	Prolonged outbreak of New Delhi metallo-beta-lactamase-producing carbapenem-resistant Enterobacterales (NDM-CRE), Tuscany, Italy, 2018 to 2019. <i>Eurosurveillance</i> , 2020, 25, .	7.0	53
71	Risk factors for recurrence in patients with <i>Clostridium difficile</i> infection due to O27 and non-O27 ribotypes. <i>Clinical Microbiology and Infection</i> , 2019, 25, 474-480.	6.0	15
72	Early alert from the microbiology laboratory improves the outcome of elderly patients with <i>Enterococcus</i> spp. bloodstream infection: Results from a multicentre prospective study. <i>Journal of Global Antimicrobial Resistance</i> , 2019, 18, 139-144.	2.2	8

#	ARTICLE	IF	CITATIONS
73	Impact of Initial Antifungal Therapy on the Outcome of Patients With Candidemia and Septic Shock Admitted to Medical Wards: A Propensity Score–Adjusted Analysis. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz251.	0.9	11
74	Immunosuppression reduction in liver and kidney transplant recipients with suspected bacterial infection: A multinational survey. <i>Transplant Infectious Disease</i> , 2019, 21, e13134.	1.7	8
75	Performance of the CHA2DS2-VASc score in predicting new onset atrial fibrillation during hospitalization for community-acquired pneumonia. <i>European Journal of Internal Medicine</i> , 2019, 62, 24-28.	2.2	15
76	Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 633-641.	2.5	13
77	Left Atrium Dilatation and Left Ventricular Hypertrophy Predispose to Atrial Fibrillation in Patients With Community-Acquired Pneumonia. <i>American Journal of Cardiology</i> , 2019, 124, 723-728.	1.6	11
78	Updates in the epidemiology and management of candidemia and <i>Clostridioides difficile</i> coinfection. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 375-382.	4.4	2
79	Antimicrobial consumption and impact of antimicrobial stewardship programmes in long-term care facilities. <i>Clinical Microbiology and Infection</i> , 2019, 25, 562-569.	6.0	41
80	Corticosteroid Use and Incident Myocardial Infarction in Adults Hospitalized for Community-acquired Pneumonia. <i>Annals of the American Thoracic Society</i> , 2019, 16, 91-98.	3.2	31
81	Identifying patients with acute bacterial skin and skin structure infection who need blood cultures. <i>Internal and Emergency Medicine</i> , 2019, 14, 203-206.	2.0	8
82	A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired Pneumonia. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	15
83	Predicting resistant etiology in hospitalized patients with blood cultures positive for Gram-negative bacilli. <i>European Journal of Internal Medicine</i> , 2018, 53, 21-28.	2.2	25
84	Pharmacokinetic drug evaluation of avibactam + ceftazidime for the treatment of hospital-acquired pneumonia. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018, 14, 331-340.	3.3	13
85	Risk Factors and Outcomes of Endocarditis Due to Non-HACEK Gram-Negative Bacilli: Data from the Prospective Multicenter Italian Endocarditis Study Cohort. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	56
86	Follow-up Blood Cultures: A 2.0 Diagnostic Tool in Patients With Gram-Negative Bacteremia and Septic Thrombophlebitis. <i>Clinical Infectious Diseases</i> , 2018, 66, 1154-1155.	5.8	12
87	Performance status and in-hospital mortality of elderly patients with community acquired pneumonia. <i>Internal and Emergency Medicine</i> , 2018, 13, 501-507.	2.0	13
88	Predictors of mortality in nursing-home residents with pneumonia: a multicentre study. <i>Clinical Microbiology and Infection</i> , 2018, 24, 72-77.	6.0	28
89	Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 984.	7.4	538
90	The GISA call to action for the appropriate use of antimicrobials and the control of antimicrobial resistance in Italy. <i>International Journal of Antimicrobial Agents</i> , 2018, 52, 127-134.	2.5	22

#	ARTICLE	IF	CITATIONS
91	Predictors of outcome in patients with severe sepsis or septic shock due to extended-spectrum β -lactamase-producing Enterobacteriaceae. International Journal of Antimicrobial Agents, 2018, 52, 577-585.	2.5	36
92	Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infectious Diseases, The, 2017, 17, 726-734.	9.1	367
93	Neglected tropical diseases in Europe: an emerging problem for health professionals. Internal and Emergency Medicine, 2017, 12, 423-424.	2.0	2
94	Cardiovascular Complications and Short-term Mortality Risk in Community-Acquired Pneumonia. Clinical Infectious Diseases, 2017, 64, 1486-1493.	5.8	162
95	Assessment of risk factors for candidemia in non-neutropenic patients hospitalized in Internal Medicine wards: A multicenter study. European Journal of Internal Medicine, 2017, 41, 33-38.	2.2	35
96	<i>Candida</i> endocarditis: systematic literature review from 1997 to 2014 and analysis of 29 cases from the Italian Study of Endocarditis. Expert Review of Anti-Infective Therapy, 2017, 15, 807-818.	4.4	23
97	Quantifying the Effects of Prior Acetyl-Salicylic Acid on Sepsis-Related Deaths: An Individual Patient Data Meta-Analysis Using Propensity Matching*. Critical Care Medicine, 2017, 45, 1871-1879.	0.9	33
98	Empiric Therapy With Carbapenem-Sparing Regimens for Bloodstream Infections due to Extended-Spectrum β -Lactamase-Producing Enterobacteriaceae: Results From the INCREMENT Cohort. Clinical Infectious Diseases, 2017, 65, 1615-1623.	5.8	43
99	Clinical and in vitro efficacy of colistin plus vancomycin and rifampin against colistin-resistant <i>Acinetobacter baumannii</i> causing ventilator-associated pneumonia. New Microbiologica, 2017, 40, 205-207.	0.1	8
100	<i>Aeromonas hydrophila</i> Endocarditis with Ruptured Mycotic Aneurysm of Right Renal Artery. Gastroenterology Insights, 2016, 8, 6515.	1.2	4
101	An empirical broad spectrum antibiotic therapy in health-care-associated infections improves survival in patients with cirrhosis: A randomized trial. Hepatology, 2016, 63, 1632-1639.	7.3	66
102	Expanded CURB-65: a new score system predicts severity of community-acquired pneumonia with superior efficiency. Scientific Reports, 2016, 6, 22911.	3.3	54
103	Role of aspirin in patients with septic shock: a complex and intriguing relationship. Intensive Care Medicine, 2016, 42, 1097-1097.	8.2	1
104	Shunt lock therapy with micafungin to treat shunt-associated <i>Candida albicans</i> meningitis in an infant: Table 1. Journal of Antimicrobial Chemotherapy, 2016, 71, 2060-2061.	3.0	7
105	Acute bacterial skin and skin structure infections in internal medicine wards: old and new drugs. Internal and Emergency Medicine, 2016, 11, 637-648.	2.0	35
106	A Multinational, Preregistered Cohort Study of β -Lactam/ β -Lactamase Inhibitor Combinations for Treatment of Bloodstream Infections Due to Extended-Spectrum- β -Lactamase-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2016, 60, 4159-4169.	3.2	137
107	High-Dose Micafungin for Preterm Neonates and Infants with Invasive and Central Nervous System Candidiasis. Antimicrobial Agents and Chemotherapy, 2016, 60, 7333-7339.	3.2	26
108	Nursing home residence is associated with spread of <i>Clostridium difficile</i> ribotype 027 in central Italy. Journal of Hospital Infection, 2016, 94, 201-203.	2.9	4

#	ARTICLE	IF	CITATIONS
109	MEDical wards Invasive Candidiasis ALgorithms (MEDICAL):Consensus proposal for management. European Journal of Internal Medicine, 2016, 34, 45-53.	2.2	8
110	Candidemia in Patients with Body Temperature Below 37Â°C and Admitted to Internal Medicine Wards: Assessment of Risk Factors. American Journal of Medicine, 2016, 129, 1330.e1-1330.e6.	1.5	16
111	Lowâ€grade endotoxemia and clotting activation in the early phase of pneumonia. Respirology, 2016, 21, 1465-1471.	2.3	29
112	Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections. Journal of Antimicrobial Chemotherapy, 2016, 71, 2713-2722.	3.0	144
113	Impaired flow-mediated dilation in hospitalized patients with community-acquired pneumonia. European Journal of Internal Medicine, 2016, 36, 74-80.	2.2	15
114	Management of candidemia in patients withClostridium difficileinfection. Expert Review of Anti-Infective Therapy, 2016, 14, 679-685.	4.4	7
115	Low-grade endotoxemia, gut permeability and platelet activation in community-acquired pneumonia. Journal of Infection, 2016, 73, 107-114.	3.3	45
116	Current features of infective endocarditis in persons on hemodialysis: a prevalence study with case control design from the prospective multicenter SEI cohort. Infection, 2016, 44, 467-474.	4.7	14
117	Hospitalization for Pneumonia is Associated With Decreased 1-Year Survival in Patients With Type 2 Diabetes. Medicine (United States), 2016, 95, e2531.	1.0	25
118	Candidaemia after heart valve replacement surgery: recurrence as prosthetic valve endocarditis is an expected over one-year complication. Clinical Microbiology and Infection, 2016, 22, 466-467.	6.0	7
119	Clinical features and outcome of patients with descending necrotizing mediastinitis: prospective analysis of 34 cases. Infection, 2016, 44, 77-84.	4.7	55
120	Predictors of outcome in ICU patients with septic shock caused by Klebsiella pneumoniae carbapenemaseâ€producing K.Âpneumoniae. Clinical Microbiology and Infection, 2016, 22, 444-450.	6.0	112
121	Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: a multinational pre-registered cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 1672-1680.	3.0	41
122	Septic shock from community-onset pneumonia: is there a role for aspirin plus macrolides combination?. Intensive Care Medicine, 2016, 42, 301-302.	8.2	16
123	Risk Factors and Outcomes for Bloodstream Infections Secondary to Clostridium difficile Infection. Antimicrobial Agents and Chemotherapy, 2016, 60, 252-257.	3.2	45
124	Spontaneous bacterial peritonitis due to methicillin-resistant Staphylococcus aureus in a patient with cirrhosis: the potential role for daptomycin and review of the literature. Gastroenterology Insights, 2015, 7, 6127.	1.2	6
125	Reply to: â€œThe Possible Role of Anti-Methicillin-Resistant Staphylococcus Aureus Antimicrobial Agents in Spontaneous Bacterial Peritonitisâ€; Gastroenterology Insights, 2015, 7, 6356.	1.2	0
126	The Spread of Multi Drug Resistant Infections Is Leading to an Increase in the Empirical Antibiotic Treatment Failure in Cirrhosis: A Prospective Survey. PLoS ONE, 2015, 10, e0127448.	2.5	78

#	ARTICLE	IF	CITATIONS
127	Relation of Cardiac Complications in the Early Phase of Community-Acquired Pneumonia to Long-Term Mortality and Cardiovascular Events. <i>American Journal of Cardiology</i> , 2015, 116, 647-651.	1.6	110
128	Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia. <i>Thorax</i> , 2015, 70, 961-966.	5.6	38
129	Linezolid-resistant staphylococcal bacteraemia: A multicentre caseâ€“control study in Italy. <i>International Journal of Antimicrobial Agents</i> , 2015, 45, 255-261.	2.5	30
130	Lower Mortality Rate in Elderly Patients With Communityâ€“Onset Pneumonia on Treatment With Aspirin. <i>Journal of the American Heart Association</i> , 2015, 4, e001595.	3.7	78
131	Risk factors and clinical outcomes of candidaemia in patients treated for <i>Clostridium difficile</i> infection. <i>Clinical Microbiology and Infection</i> , 2015, 21, 493.e1-493.e4.	6.0	29
132	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1493-1494.	2.8	2
133	Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia. <i>European Journal of Internal Medicine</i> , 2015, 26, 330-337.	2.2	25
134	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1489-1490.	2.8	2
135	Reply. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1491-1492.	2.8	1
136	Optimizing antibiotic therapy of bacteremia and endocarditis due to staphylococci and enterococci: New insights and evidence from the literature. <i>Journal of Infection and Chemotherapy</i> , 2015, 21, 330-339.	1.7	33
137	Individualizing Risk of Multidrug-Resistant Pathogens in Community-Onset Pneumonia. <i>PLoS ONE</i> , 2015, 10, e0119528.	2.5	55
138	Abstract 16055: Ongoing Prothrombotic State in the Early Phase of Pneumonia. <i>Circulation</i> , 2015, 132, .	1.6	0
139	Severe community onset healthcare-associated <i>Clostridium difficile</i> infection complicated by carbapenemase producing <i>Klebsiella pneumoniae</i> bloodstream infection. <i>BMC Infectious Diseases</i> , 2014, 14, 475.	2.9	4
140	Non-invasive ventilation in the treatment of sleep-related breathing disorders: A review and update. <i>Revista Portuguesa De Pneumologia</i> , 2014, 20, 324-335.	0.7	22
141	Reply to Di Paolo et al. <i>Clinical Infectious Diseases</i> , 2014, 58, 1789-1790.	5.8	6
142	CAP and HCAP are different? An unresolved question. <i>Thorax</i> , 2014, 69, 676-677.	5.6	2
143	Early, intermediate and late infectious complications after transcatheter or surgical aortic-valve replacement: a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2014, 20, 758-763.	6.0	18
144	Multimorbidity and polypharmacy in the elderly: lessons from REPOSI. <i>Internal and Emergency Medicine</i> , 2014, 9, 723-734.	2.0	121

#	ARTICLE	IF	CITATIONS
145	Healthcare-associated pneumonia: a never-ending story. <i>Gastroenterology Insights</i> , 2014, 6, 5387.	1.2	2
146	Simplified Equations Using Two Concentrations To Calculate Area under the Curve for Antimicrobials with Concentration-Dependent Pharmacodynamics: Daptomycin as a Motivating Example. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3162-3167.	3.2	36
147	Early identification of severe community-onset pneumonia in "frail elderly patient". <i>Internal and Emergency Medicine</i> , 2014, 9, 119-120.	2.0	6
148	A cluster of fulminant <i>Clostridium difficile</i> colitis in an intensive care unit in Italy. <i>Infection</i> , 2014, 42, 585-589.	4.7	13
149	Healthcare-Associated Pneumonia and Multidrug-Resistant Bacteria: Do We Have a Convincing Answer?. <i>Clinical Infectious Diseases</i> , 2014, 58, 1196-1197.	5.8	5
150	ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients. <i>Clinical Microbiology and Infection</i> , 2014, 20, 1-55.	6.0	640
151	Platelet Activation Is Associated With Myocardial Infarction in Patients With Pneumonia. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1917-1925.	2.8	134
152	Gout, allopurinol intake and clinical outcomes in the hospitalized multimorbid elderly. <i>European Journal of Internal Medicine</i> , 2014, 25, 847-852.	2.2	1
153	Gender-differences in disease distribution and outcome in hospitalized elderly: Data from the REPOSI study. <i>European Journal of Internal Medicine</i> , 2014, 25, 617-623.	2.2	75
154	Identification and management of invasive mycoses in internal medicine: a road-map for physicians. <i>Internal and Emergency Medicine</i> , 2014, 9, 501-511.	2.0	23
155	Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI). <i>BMC Infectious Diseases</i> , 2014, 14, 230.	2.9	71
156	Is NOX2 Upregulation Implicated in Myocardial Injury in Patients with Pneumonia?. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 2949-2954.	5.4	25
157	Predictors of mortality in non-neutropenic patients with invasive pulmonary aspergillosis: does galactomannan have a role?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2014, 80, 83-86.	1.8	20
158	Role of empirical and targeted therapy in hospitalized patients with bloodstream infections caused by ESBL-producing Enterobacteriaceae. <i>Annali Di Igiene: Medicina Preventiva E Di Comunita</i> , 2014, 26, 293-304.	0.7	12
159	Patient risk factors for outer membrane permeability and KPC-producing carbapenem-resistant <i>Klebsiella pneumoniae</i> isolation: results of a double case-control study. <i>Infection</i> , 2013, 41, 61-67.	4.7	57
160	Successful Ertapenem-Doripenem Combination Treatment of Bacteremic Ventilator-Associated Pneumonia Due to Colistin-Resistant KPC-Producing <i>Klebsiella pneumoniae</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2900-2901.	3.2	86
161	Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?. <i>Journal of Infection and Chemotherapy</i> , 2013, 19, 732-739.	1.7	65
162	Topical nystatin prophylaxis: a likely viable measure for reducing impact of candidemia in neurosurgical patients with early tracheostomy intubation. <i>Critical Care</i> , 2013, 17, 414.	5.8	2

#	ARTICLE	IF	CITATIONS
163	Daptomycin plus trimethoprim/sulfamethoxazole combination therapy in post-neurosurgical meningitis caused by linezolid-resistant <i>Staphylococcus epidermidis</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2013, 76, 99-102.	1.8	24
164	Ampicillin Plus Ceftriaxone Is as Effective as Ampicillin Plus Gentamicin for Treating <i>Enterococcus faecalis</i> Infective Endocarditis. <i>Clinical Infectious Diseases</i> , 2013, 56, 1261-1268.	5.8	241
165	Considerations for Higher Doses of Daptomycin in Critically Ill Patients With Methicillin-Resistant <i>Staphylococcus aureus</i> Bacteremia. <i>Clinical Infectious Diseases</i> , 2013, 57, 1568-1576.	5.8	118
166	Candidemia Subsequent to Severe Infection Due to <i>Clostridium difficile</i> : Is There a Link?. <i>Clinical Infectious Diseases</i> , 2013, 57, 772-774.	5.8	29
167	Worrisome Trend of New Multiple Mechanisms of Linezolid Resistance in Staphylococcal Clones Diffused in Italy. <i>Journal of Clinical Microbiology</i> , 2013, 51, 1256-1259.	3.9	20
168	Rapidly Fatal Hemorrhagic Pneumonia and Group A <i>Streptococcus</i> Serotype M1. <i>Emerging Infectious Diseases</i> , 2013, 20, 98-101.	4.3	13
169	Candidal thrombophlebitis of central veins: case report and review. <i>Medical Mycology</i> , 2012, 50, 299-304.	0.7	14
170	Daptomycin serum levels in critical patients undergoing continuous renal replacement. <i>Journal of Chemotherapy</i> , 2012, 24, 253-256.	1.5	21
171	Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian Study on Endocarditis. <i>Infection</i> , 2012, 40, 527-535.	4.7	128
172	Retrospective case-control analysis of patients with staphylococcal infections receiving daptomycin or glycopeptide therapy. <i>International Journal of Antimicrobial Agents</i> , 2012, 39, 64-68.	2.5	36
173	Clinical impact of broad-spectrum empirical antibiotic therapy in patients with healthcare-associated pneumonia: a multicenter interventional study. <i>Internal and Emergency Medicine</i> , 2012, 7, 523-531.	2.0	28
174	Pneumonia in frail older patients: an up to date. <i>Internal and Emergency Medicine</i> , 2012, 7, 415-424.	2.0	30
175	Changing Italian nosocomial-community trends and heteroresistance in <i>Staphylococcus aureus</i> from bacteremia and endocarditis. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2012, 31, 739-745.	2.9	41
176	Community-acquired MRSA: a potentially dangerous but invisible enemy. <i>Minerva Anestesiologica</i> , 2012, 78, 865-7.	1.0	3
177	Role of multidrug-resistant pathogens in health-care-associated pneumonia. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 11-12.	9.1	14
178	Healthcare-associated pneumonia: Diagnostic criteria and distinction from community-acquired pneumonia. <i>International Journal of Infectious Diseases</i> , 2011, 15, e545-e550.	3.3	55
179	Risk factors and clinical significance of ertapenem-resistant <i>Klebsiella pneumoniae</i> in hospitalised patients. <i>Journal of Hospital Infection</i> , 2011, 78, 54-58.	2.9	54
180	Performance of PSI, CURB-65, and SCAP scores in predicting the outcome of patients with community-acquired and healthcare-associated pneumonia. <i>Internal and Emergency Medicine</i> , 2011, 6, 431-436.	2.0	58

#	ARTICLE	IF	CITATIONS
181	Surveillance and management of multidrug-resistant microorganisms. Expert Review of Anti-Infective Therapy, 2011, 9, 653-679.	4.4	54
182	Invasive aspergillosis in patients with liver disease. Medical Mycology, 2011, 49, 406-413.	0.7	78
183	Invasive Pulmonary Aspergillosis in Non-Neutropenic Patients: Analysis of a 14-Month Prospective Clinical Experience. Journal of Chemotherapy, 2011, 23, 290-294.	1.5	18
184	Clinical Experience of Anidulafungin for the Treatment of Patients with Documented Candidemia. Journal of Chemotherapy, 2010, 22, 397-401.	1.5	3
185	Prolonged bacteraemia caused by VIM-1 metallo- β -lactamase-producing <i>Proteus mirabilis</i> : first report from Italy. Clinical Microbiology and Infection, 2010, 16, 179-181.	6.0	14
186	Surgical debridement with muscle flap transposition and systemic teicoplanin therapy for infected hip arthroplasty. HIP International, 2010, 20, 255-257.	1.7	8
187	Septic bilateral pulmonary candidiasis successfully treated with anidulafungin therapy in two patients with peritoneal carcinomatosis. Journal of Antimicrobial Chemotherapy, 2010, 65, 2266-2267.	3.0	5
188	Cirrhotic Patients Are at Risk for Health Care-Associated Bacterial Infections. Clinical Gastroenterology and Hepatology, 2010, 8, 979-985.e1.	4.4	274
189	Infections with VIM-1 Metallo- β -Lactamase-Producing <i>Enterobacter cloacae</i> and Their Correlation with Clinical Outcome. Journal of Clinical Microbiology, 2009, 47, 3514-3519.	3.9	54
190	Clonal Multidrug-Resistant <i>Corynebacterium striatum</i> Strains, Italy. Emerging Infectious Diseases, 2009, 15, 75-78.	4.3	64
191	Outcomes of Patients Hospitalized With Community-Acquired, Health Care-Associated, and Hospital-Acquired Pneumonia. Annals of Internal Medicine, 2009, 150, 19.	3.9	267
192	Serious infections due to methicillin-resistant <i>Staphylococcus aureus</i> : An evolving challenge for physicians. European Journal of Internal Medicine, 2009, 20, 343-347.	2.2	34
193	<i>Candida</i> Infective Endocarditis. Medicine (United States), 2009, 88, 160-168.	1.0	113
194	In vitro activity of daptomycin against methicillin- and multi-resistant <i>Staphylococcus haemolyticus</i> invasive isolates carrying different mec complexes. Diagnostic Microbiology and Infectious Disease, 2008, 61, 227-231.	1.8	15
195	Class I Integron-Borne <i>bla</i> _{VIM-1} Carbapenemase in a Strain of <i>Enterobacter cloacae</i> Responsible for a Case of Fatal Pneumonia. Microbial Drug Resistance, 2008, 14, 45-47.	2.0	18
196	Health Care-Associated Pneumonia: A New Clinical Entity. Archives of Internal Medicine, 2008, 168, 109.	3.8	4
197	<i>Staphylococcus haemolyticus</i> endocarditis: clinical and microbiologic analysis of 4 cases. Diagnostic Microbiology and Infectious Disease, 2007, 57, 325-331.	1.8	33
198	Teicoplanin use and emergence of <i>Staphylococcus haemolyticus</i> : is there a link?. Clinical Microbiology and Infection, 2006, 12, 96-97.	6.0	22

#	ARTICLE	IF	CITATIONS
199	Successful Conservative Treatment of Descending Necrotizing Mediastinitis With Fistula Formation in the Hypopharynx. <i>Infectious Diseases in Clinical Practice</i> , 2005, 13, 36-38.	0.3	1
200	Methicillin-Resistant Staphylococcal Bacteremia in Patients with Hematologic Malignancies: Clinical and Microbiological Retrospective Comparative Analysis of <i>S. haemolyticus</i> , <i>S. epidermidis</i> and <i>S. aureus</i> . <i>Journal of Chemotherapy</i> , 2004, 16, 540-548.	1.5	32
201	Conservative medical therapy of prosthetic joint infections: retrospective analysis of an 8-year experience. <i>Clinical Microbiology and Infection</i> , 2004, 10, 831-837.	6.0	74
202	<i>Staphylococcus aureus</i> bacteremia in patients with hematologic malignancies: a retrospective case-control study. <i>Haematologica</i> , 2003, 88, 923-30.	3.5	39
203	Conservative Medical Therapy of Infections Following Osteosynthesis: a Retrospective Analysis of a Six-Year Experience. <i>Journal of Chemotherapy</i> , 2002, 14, 378-383.	1.5	13